Investigational drug · Phase 2
SAR439459
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Plasma Cell Myeloma Refractory.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
4
Any phase or sponsor naming "SAR439459"
First trial start
2021
Jan 25, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SAR439459", any sponsor or status.
Conditions studied
As listed on its trial records.
- Plasma Cell Myeloma Refractory
Approved drugs for the same conditions: Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "SAR439459" as an intervention, largest first.
- Isatuximab in Combination With Novel Agents in RRMM - Master ProtocolPivotal-lookingRecruiting
SanofiSanofi (SNY)
NCT04643002 · 258 participants (planned) · Start Jan 25, 2021 · Primary completion Sep 13, 2027
Drug: Isatuximab; Dexamethasone and 6 more · For: Plasma Cell Myeloma Refractory
Sites: Birmingham, Alabama; Atlanta, Georgia; Chicago, Illinois · 28 sites in all
- A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid TumorsPivotal-lookingCompleted
SanofiSanofi (SNY)
NCT03192345 · 161 participants · Start Jun 9, 2017 · Primary completion Dec 21, 2021
Drug: SAR439459; Cemiplimab REGN2810 · For: Malignant Solid Tumor
Sites: Fairway, Kansas; Boston, Massachusetts; Durham, North Carolina · 34 sites in all
SanofiSanofi (SNY)
NCT05231668 · 16 participants · Start Aug 25, 2022 · Primary completion Nov 12, 2024
Drug: SAR439459; Placebo · For: Osteogenesis Imperfecta
Sites: Los Angeles, California; New Haven, Connecticut; Indianapolis, Indiana · 13 sites in all
M.D. Anderson Cancer CenterAcademic, hospital or other
NCT04729725 · 3 participants · Start Feb 9, 2021 · Primary completion Dec 2, 2022
Drug: Anti-TGF-beta Monoclonal Antibody SAR-439459; Cemiplimab · For: Advanced Malignant Solid Neoplasm; Metastatic Malignant Solid Neoplasm; Unresectable Malignant Solid Neoplasm
Sites: Houston, Texas
Newest research
PubMed records naming it or its code names, newest first.
- Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
Baranda JC, Robbrecht D, Sullivan R, et al. · Clin Transl Sci 2024
- Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
Robbrecht D, Grob JJ, Bechter O, et al. · Clin Transl Sci 2024
- Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade.
Greco R, Qu H, Qu H, et al. · Oncoimmunology 2020
Also in development for Plasma Cell Myeloma Refractory
- EvorpaceptALX148Phase 25 trials
ALX Oncology Inc. · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Breast Cancer, Metastatic
- PegenzileukinSAR444245Phase 21 trial
Sanofi · Plasma Cell Myeloma Refractory
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Sanofi.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.